Skip to main content

Table 4 HIV-1 patient information and CTL responses to peptide pools

From: Elicitation from virus-naive individuals of cytotoxic T lymphocytes directed against conserved HIV-1 epitopes

  PATIENT INFORMATION CTL RESPONSES TO PEPTIDE POOLS AS DETERMINED BY INTERFERON-GAMMA ELISPOT (SFC*)
PATIEND ID HLA TYPE DISEASE STAGE* HAART* ON HAART SINCE INFECTED SINCE VL* PBMC DATE* Pool 1 Pool 1 Pool 2 Pool 2 Pool 3 Pool 3 Pool 4 Pool 4 Pool 5 Pool 5 CEF* NEG NEG NEG POS
1 Unavailable Unavailable Unavailable NA Unavailable Unavailable 6/22/04 1860 1610 530 510 700 620 10 10 10 10 0 0 0 0 PPP
2 Unavailable Unavailable Unavailable NA Unavailable Unavailable 2/17/04 910 960 20 0 40 40 0 0 10 10 0 20 0 0 PPP
3 Unavailable Chronic No NA Unknown >750000 2/19/04 0 0 0 10 0 0 0 0 0 0 675 0 0 0 PP
4 Unavailable Chronic No NA Unknown >750000 2/26/04 0 0 0 0 0 0 0 0 0 0 70 0 0 0 PPP
5 Unavailable Chronic No NA Unknown 12905 3/4/04 110 150 60 80 90 70 50 30 30 40 266 60 40 50 PPP
6 Unavailable Chronic Yes 4/18/01 Unknown 176 2/26/04 180 130 150 200 150 150 210 250 100 120 163 0 0 0 PPP
7 Unavailable Chronic Yes 1/26/03 Unknown 6030 2/19/04 0 0 0 0 0 0 0 0 0 10 60 0 0 0 PPP
8 Unavailable Chronic Yes NA Unknown >750000 2/24/04 0 0 0 0 0 0 0 0 0 0 >1000 0 0 0 PPP
9 Unavailable Chronic No NA Unknown >500000 2/19/04 0 0 10 0 30 20 170 150 0 0 540 0 0 0 PP
10 Unavailable Chronic No NA Unknown 35100 2/26/04 1440 1010 1010 760 1040 1070 1050 1080 1270 1160 >1000 10 20 40 PPP
11 Unavailable Chronic No NA Unknown 236000 3/2/04 10 10 30 30 20 20 30 30 30 40 20 10 30 10 PPP
12 Unavailable Chronic No NA Unknown 9030 2/19/04 0 0 0 0 0 0 0 0 0 0 140 0 0 0 PP
13 Unavailable Chronic No NA Unknown 12000 3/4/04 260 210 190 160 180 210 150 210 150 160 >1000 10 20 0 PPP
14 A11/74, B35/44, C4/5 Chronic No NA Unknown 74 4/20/04 0 0 0 0 0 0 0 0 0 0 833 0 0 0 PPP
15 A30/33, B13/14, C5/8 Chronic No NA Unknown 122 4/20/04 60 90 20 0 20 10 20 10 20 20 0 0 10 10 PPP
16 A25/32, B18/40, C2/12 Chronic No NA Unknown 12700 4/20/04 420 410 340 350 220 370 550 490 620 500 0 10 10 0 PPP
17 a2/30, b44/57, c5/18 Chronic No NA Unknown 49 4/27/04 380 380 420 470 330 410 490 500 360 250 953 0 0 0 PPP
18 A1/74, B57/81, C7/18 Chronic No NA Unknown 845 6/3/04 0 20 0 20 10 10 10 0 20 20 ND 0 0   10 PP
19 A3/33, B15/49, C7/14 Chronic No NA Unknown 49 6/16/04 350 350 170 140 230 270 220 240 110 90 ND 0 0   10 PPP
20 A29, B44, C16 Chronic No NA Unknown 807 6/16/04 210 180 130 180 200 260 0 20 0 0 ND 0 10   0 PPP
21 A1/24, B13/57, C6 Acute No NA Unknown 5490 6/22/04 130 120 110 120 270 230 0 0 0 0 60 0 10 0 PPP
22 A1/24, B8/35, C4/7 Acute Yes 7/21/03 2002, May <50 2/17/04 130 100 30 50 70 40 120 100 70 50 347 0 0 0 PPP
23 A24/32, B35/41, C4/17 Acute Yes 6/1/02 2002, Jun <50 2/19/04 0 0 0 0 0 0 260 300 200 140 146 0 0 10 PPP
24 A2/31, B40/44, C3/16 Acute Yes 9/2/03 2003, Aug <400 2/26/04 0 0 0 0 0 0 0 0 0 0 440 0 0 0 PPP
25 A11/30, B15/35, C3/4 Acute Yes 12/30/03 2003, Dec <400 2/26/04 20 30 10 30 20 30 30 40 10 30 396 20 0 20 PPP
26 A11/24, B35/38, C4/7 Acute Yes 5/19/99 1999, may <50 3/1/04 0 0 0 0 0 0 0 0 0 0 60 0 20 0 PPP
27 A1/24, B14/35, C4/8 Acute Yes 9/8/03 2003, JUL <400 3/1/04 40 50 40 30 30 60 10 50 30 10 100 0 0 20 PPP
28 A1/11, B18/52, C12 Acute Yes 8/25/99 1999, SEP <50 3/9/04 0 0 0 0 0 0 0 0 0 0 520 0 0 0 PPP
29 A3/68, B14/44, B8/16 Acute Yes 9/2/03 2003, AUG <50 3/9/04 250 320 50 50 40 20 0 0 20 20 140 0 0 0 PPP
30 A1/32, B7/44, C7/16 Acute Yes 2/18/04 2004, FEB 5,440 4/20/04 40 20 100 90 120 110 170 120 180 220 433 0 0 0 PPP
31 A2/3, B7/44, C5/7 Acute Yes 8/1/97 1997-AUG 149 4/20/04 20 0 0 0 0 0 10 0 0 0 443 0 10 0 PP
32 A33, B53, C4 Acute Yes 12/14/00 2000-NOV <50 4/22/04 0 0 0 0 0 0 0 0 0 0 0 0 0 0 PPP
33 A1/68, B7/8, C7/7 Acute Yes 4/23/04 2004-APR 853 5/6/04 10 10 0 0 0 0 0 10 0 0 ND 0 0 0 PPP
34 A3/24, B40/57, C3/7 Acute Yes 11/5/03 2003-NOV <50 5/12/04 220 170 190 170 190 120 10 30 0 10 0 30 10 20 PPP
35 A26/68, B44/71, C3/7 Acute Yes 12/22/98 1996-NOV <50 5/13/04 0 0 0 20 10 10 0 10 10 10 20 10 10 10 PPP
36 A2/26, B53/57, C4/18 Acute Yes 5/24/01 2001, MAY <400 6/23/04 0 0 0 0 0 10 0 0 0 0 0 0 10 0 PPP
37 A2/74, B51/53, C4/14 Acute Yes 8/22/01 2001, AUG <50 6/22/04 0 10 0 10 20 20 0 20 0 10 986 0 0 0 PPP
38 A1/2, B8/15, C3/7 Acute Yes 3/9/99 1999, MAR 1,111 5/19/04 420 430 480 420 500 410 430 410 430 480 326 0 0 0 PPP
39 A1/2, B7/8, C7/7 Acute No 7/22/02 2002, JUL <400 3/2/04 10 20 10 10 0 10 10 0 0 10 >1000 0 0 10 PPP
40 A23/24, B44/60, C3/14 Acute No NA 2004, FEB 1,580 3/15/04 210 220 90 90 80 100 0 0 0 0 70 0 20 0 PPP
41 A1/3, B8/15, C7 Acute No NA 2003, AUG 56,100 4/14/04 260 210 380 480 360 290 300 430 430 440 ND 0 0 0 PPP
42 A2/31, B15/51, C3/15 Acute No NA 2003-MAY 2,620 6/3/04 410 430 480 410 490 430 440 410 400 470 116 0 0 20 PPP
43 A3/24, B14/35, C8/12 Acute No NA 2000-MAY 883 5/26/04 250 250 40 30 20 40 40 40 40 30 80 0 0 10 PPP
44 A1/3, B35/40, C4/15 Acute No NA 2003-OCT 121,000 5/13/04 910 1150 1010 1010 1100 1080 980 1330 930 1090 260 0 0 0 PPP
45 A3/41, B14/35, C8/12 Acute No NA 2002, FEB 29,000 6/22/04 950 1090 30 40 40 60 40 40 50 60 143 0 0 0 PPP
46 A2/32, B15/39, C4/15 Acute No NA 2001, OCT 48,000 6/23/04 1200 1200 1150 1460 1660 1300 1460 1290 1390 1540 160 0 10 10 PPP
47 A3/68, B35/44, C4/7 Acute No NA 1999, AUG 667 5/26/04 10 30 0 30 10 20 0 20 10 0 ND 0 20 10 PPP
  1. CTL responses were determined by the interferon-gamma elispot assay
  2. SFC*: Spot Forming Colonies
  3. DISEASE STAGE*: refers to the stage at the time of diagnosis
  4. HAART*: Patients were receiving HAART treatment at the time of PBMC collection
  5. VL*: Viral Load at the time of PBMC sampling in copies/ml
  6. PBMC DATE*: Date PBMC samples were collected
  7. CEF: Response to CMV, EBV and Influenza A peptide pools.
  8. POS is a PHA response where PP = high and PPP = highest responses related to non-stimulated controls. Both PP and PPP are equivalent to responses form normal individuals.
  9. NA, Not Applicable